philipn / COVID-19 therapeutics c6c05dedc7a16d0932207fab4e219f17d1b6fae2

Create Draft
Reword introduction
Review changes View this version of the page
You can also use the and keys
Deletions are marked like this Additions are marked like this

This page details potential COVID-19 theraputics. Substances listed here are not necessarily effective. Potential medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Theraputic is another word for a treatment. Theraputics are drugs that can be given to someone once (or shortly before) they have been infected by SARS-CoV-2. Vaccines, in contrast, are given before an infection happens and protect against the development of disease.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • GS-441524
  • MK-4482 (formerly known as EIDD-2801)
  • AT-527
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Itraconazole
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Amodiaquine
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

See also

This page details potential COVID-19 therapeutics. Theraputic is another word for a treatment. Vaccines are given before someone gets COVID-19 and protects the person from infection, whereas theraputics are given when someone gets sick with COVID-19.

Substances listed here are not necessarily effective. Medications are detailed because they are on trial for use in COVID-19 or have been described as a potential treatment in an academic paper.

Anti-virals

Potential neutralizing strategies as described in "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China". Photo CC-BY Robert L. Kruse.
  • Convalescent plasma
  • Remdesivir
  • GS-441524
  • MK-4482 (formerly known as EIDD-2801)
  • AT-527
  • Favipiravir
  • Hydroxychloroquine and Chloroquine
  • Dipyridamole
  • Niclosamide
  • Nitazoxanide
  • Doxycycyline
  • Ciclesonide
  • Interferons
  • Camostat mesylate
  • Indomethacin
  • Itraconazole
  • Bromhexine
  • Galidesivir
  • Monoclonal Antibodies
  • Amodiaquine
  • Soluable ACE2 / ACE2-fc

Host response / anti-inflammatory

See also
Create Draft
Contributed by
Except where otherwise noted, text content is licensed under a Creative Commons Attribution-ShareAlike License. See copyright information.